News stories about Horizon Therapeutics (NASDAQ:HPTX) have been trending positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Therapeutics earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.995550185969 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Horizon Therapeutics (HPTX) opened at $45.99 on Thursday. Horizon Therapeutics has a fifty-two week low of $20.23 and a fifty-two week high of $46.96.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/16/horizon-therapeutics-hptx-receiving-positive-news-coverage-report-shows.html.

About Horizon Therapeutics

Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.

Insider Buying and Selling by Quarter for Horizon Therapeutics (NASDAQ:HPTX)

Receive News & Stock Ratings for Horizon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Inc and related stocks with our FREE daily email newsletter.